<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01385111</url>
  </required_header>
  <id_info>
    <org_study_id>NCC-EUSEBUS</org_study_id>
    <nct_id>NCT01385111</nct_id>
  </id_info>
  <brief_title>Combined Application of EBUS and EUS in Lung Cancer</brief_title>
  <official_title>Combined Application of EBUS-TBNA and EUS-B-FNA in Mediastinal Staging of Lung Cancer; EBUS-TBNA Centered Procedure vs. EUS-B-FNA Centered Procedure, a Randomized Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate a diagnostic yield and performance characteristics according
      to the order of endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA)
      and endoscopic ultrasound-with bronchoscope-guided transbronchial needle aspiration
      (EUS-B-FNA) in the mediastinal staging of potentially operable lung cancer. EUS-FNA is a
      better tolerated procedure than EBUS-TBNA. Therefore, EUS-B-FNA can be the main procedure in
      a combined approach with EBUS-TBNA and EUS-B-FNA. In group A, the investigators perform
      EBUS-TBNA first and EUS-B-FNA is performed when necessary. In group B, EUS-B-FNA is first
      applied and EBUS-TBNA is performed when necessary. The hypothesis is that the diagnostic
      yield of the EUS centered procedure is as good as that of the EBUS centered procedure and the
      EUS centered procedure is more tolerable than the EBUS centered procedure. We evaluate
      diagnostic yields and performance characteristics of each group.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic accuracy</measure>
    <time_frame>When the confimative disgnosis is available in all subjects (after surgery) ; 8-12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedure time</measure>
    <time_frame>During and just after the procedure ; 5-60 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular measurement (change of blood pressure, changes of heart rate, number of patients with arrhythmia)</measure>
    <time_frame>During the procedure; 0-60 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of desaturation</measure>
    <time_frame>During the procedure; 0-60minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discomfort by the procedure</measure>
    <time_frame>After the procedure ; 2-3hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse Events (infection, bleeding requiring intervention, pneumothorax, or any complications requiring hospital admission)</measure>
    <time_frame>During and after the procedure; 0-2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymph node features</measure>
    <time_frame>During and after the procedure; 0-2hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fentanyl/midazolam/lidocaine consumption</measure>
    <time_frame>After the procedure ; 1-2 hrs</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">162</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EBUS centered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EUS centered</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>EUS-B-FNA followed by EBUS-TBNA</intervention_name>
    <description>EUS-B-FNA will be performed followed by EBUS-TBNA when additional needle aspiration is necessary after EBUS-TBNA.</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>EBUS-TBNA followed by EUS-B-FNA</intervention_name>
    <description>EBUS-TBNA will be performed followed by EUS-B-FNA when additional needle aspiration is necessary after EUS-B-FNA</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed or strongly suspected non-small cell lung cancer (NSCLC)

          -  Potentially operable patients

        Exclusion Criteria:

          -  M1 disease

          -  Inoperable T4 disease

          -  Mediastinal infiltration or extranodal invasion of the mediastinal lymph node visible
             on chest CT.

          -  Confirmed supraclavicular lymph node metastasis

          -  Pancoast tumors

          -  Medically inoperable patients

          -  Contraindications for bronchoscopy and esophageal endoscopy

          -  Drug reaction to lidocaine, midazolam,fentanyl

          -  Pregnancy

          -  Ground glass-dominant nodule ( &lt; 3cm)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bin Hwangbo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Doctor, Senior Researcher</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Center (NCC) Korea</name>
      <address>
        <city>Goyang</city>
        <state>Gyeonggi-do</state>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2011</study_first_submitted>
  <study_first_submitted_qc>June 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2011</study_first_posted>
  <last_update_submitted>October 17, 2012</last_update_submitted>
  <last_update_submitted_qc>October 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2012</last_update_posted>
  <responsible_party>
    <name_title>Bin, Hwangbo</name_title>
    <organization>National Cancer center</organization>
  </responsible_party>
  <keyword>endobronchial ultrasound</keyword>
  <keyword>endoscopic ultrasound</keyword>
  <keyword>EBUS-TBNA</keyword>
  <keyword>EUS-FNA</keyword>
  <keyword>EUS-B-FNA</keyword>
  <keyword>lung cancer</keyword>
  <keyword>staging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

